- Organized by DahShu IDSWG Oncology
- Date: Friday, May 1, 2026
- Time: 8:30am – 5:00pm Eastern Daylight Saving Time (New York)
- Lunch Break: 12:00pm – 1:00pm
- FREE but require Registration Here.
- Deadline for in-person attendees: April 17, 2026. In-person attendance will be limited to a maximum of 100 participants to accommodate venue capacity limitations and cost constraints.
- Deadline for virtual attendees: April 24, 2026.
- Dial-In information will be provided for registered participants prior to the event.
- Posters
- You are encouraged to submit posters. Poster presenter must be in-person.
- Poster Abstract: Deadline April 1st, 2026. Authors will be notified regarding poster acceptance decisions prior to the event.
- Poster Submission: Click here for poster size guidelines and to submit your poster abstract.
Objective
We are excited to announce an upcoming Key Opinion Leaders (KOL) Roundtable Discussion focused on “Biomarkers in Oncology Clinical Development.” This event brings together leading experts from academia, industry, and regulatory agencies to discuss how biomarker-driven strategies are transforming oncology drug development—from early discovery to late-phase clinical trials.
During this interactive session, panelists will explore key topics including biomarker-based patient selection, translational study design, regulatory considerations, and integration of data science and AI in biomarker discovery. Attendees will gain valuable insights into current challenges, innovative methodologies, and future directions that are shaping precision oncology.
Whether you are a clinician, statistician, data scientist, or regulatory professional, this roundtable offers a unique opportunity to learn from leaders, exchange perspectives, and network with peers driving innovation in cancer research.
Join us as we advance the conversation on leveraging biomarkers to bring safer, more effective therapies to patients faster.
Keynote Speaker
- Margaret Gamalo, PhD, FASA, Pfizer
Panelists and Speakers
- Statistics
- Jonathon Vallejo, FDA
- Liz Garrett-Mayer, ASCO
- Paul Newcombe, GSK
- Kui Shen, Bayer
- Yaji Xu, Johnson & Johnson
- Gina D’Angelo, AstraZeneca
- Heng Zhou, Merck
- David Zhang, GENMAB
- AI
- Etai Jacob, AstraZeneca
- Clinical
- Jean Fan, MD, MSc. CMO, TransThera Sciences
- Antonio Tito Fojo, MD, Herbert Irving Comprehensive Cancer Center, Columbia University and James J Peters VA Medical Center
- Kaveri Suryanarayan, MD, Takeda
- Precision / Translational Medicine
- Ryan Hartmaier, AstraZeneca
- Hongfang Wang, Sanofi
- Mohini Rajasagi, Daiichi Sankyo
- Regulatory Affairs
- Jai Pandey, Sanofi
Program Schedule (Tentative)
| Time (Eastern Daylight Saving Time) | Session | Title |
| 08:30AM – 09:00AM | Session 1 | Opening Remarks & Keynote |
| 09:00AM – 10:20AM | Session 2 | Biomarkers in Early Drug Development: From Target Identification to Preclinical Validation |
| 10:30AM – 12:00PM | Session 3 | Methodologies for Prognostic and Predictive Biomarker Identification and Evaluation |
| 12:00PM – 1:00PM | lunch | Poster session |
| 01:00PM – 02:20PM | Session 4 | Advanced Biomarker-Driven Clinical Trial Designs |
| 02:30PM – 03:55PM | Session 5 | Companion diagnostic (CDx) and case-studies |
| 04:05PM – 05:30PM | Session 6 | Leveraging Artificial Intelligence and Machine Learning for Biomarker Discovery and Prediction |
| 05:30PM – 05:45PM | Closing | Closing remarks |
Program Committee
- Gina D’Angelo, AstraZeneca (Chair)
- Hong Wang, Sanofi (Chair)
- Gu Mi, Sanofi
- Judong Shen, Merck
- Kevin Dobbin, Augusta
- Shuguang Huang, Stat4ward
- Cindy Lu, AstraZeneca
- Xiaowen Tian, AstraZeneca
- Haijun Ma, Exelixis
- Di Ran, AstraZeneca
- Sutan Wu, Daiichi Sankyo
- Philip He, Daiichi Sankyo
- Pat Mitchell, AstraZeneca
- Revathi Ananthakrishnan, BMS
- Luke Ouma, Astrazeneca
- Jingxiao Chen, Regeneron
- Yujun Wu, Eli Lilly
- Nicole Li, BeOne Medicines
- Jun Yin, Alexion
- Yashvi Bhandari, Winston Churchill High School
- Erica (Xin) Tong, Takeda
- Heng Zhou, Merck
Location
- To be announced
Directions and Hotels: To be provided
Virtual Participants: The meeting link will be provided by email prior to the event.
Sponsor
We will plan similar events in the future for various practical topics in oncology drug development. If you would like to sponsor our events (501(c)(3)), please contact us.
Dahshu IDSWG Oncology 